Mylan has launched in the UK the first generic formulation of Teva’s multiple sclerosis blockbuster Copaxone, offering a potentially cheaper alternative for treatment of relapsing forms of the condition.
The move follows a court battle during which Teva tried to block the launch of Brabio (glatiramer acetate injection).
However, earlier this month, the UK's Court of Appeal refused Teva’s request to appeal the UK High Court of Justice’s decision in favour of Mylan and its European partner Synthon, finding all claims of Teva's patent in question “invalid based on obviousness”.
It is expected that Brabio will be available at a lower acquisition cost to the health service, which Mylan says fits with the current drive to expand use of best value medicines via the NHS’ Medicines Value Programme.
This initiative aims to facilitate access to treatment that is clinically effective, based on the latest scientific discovery, at as low a price as possible, so that maximum funds can be diverted to other areas of need without compromising on treatment.
“Bringing a more affordable, more accessible treatment option to market for patients with multiple sclerosis has been a priority for Mylan,” commented Mylan Europe president Jacek Glinka.
“Approximately 100,000 people in the UK live with MS, and today’s launch of Brabio demonstrates our commitment to those patients and healthcare professionals.”